The LMB’s Michael Hastings talks to the BBC’s Science in Action programme about the latest advance in body clock research. More…
Science in Action: Can We Cure Jet Lag?
2013 Max Perutz Science Writing Award shortlist
Clara Sidor, CDF in the LMB’s Cell Biology Division, is shortlisted for the Max Perutz Science Writing Award. More…
Biological clocks defy circadian rhythms
The LMB’s Mick Hastings is amongst a group of scientists that have shown marine animals have tidal and monthly timekeepers that work independently of daily cycle. More…
Drug developed in Cambridge approved for treatment of multiple sclerosis
Approval concludes nearly 40-year epic journey from fundamental research, begun at LMB, to discovery of an effective treatment for active relapsing multiple sclerosis. More…
Monoclonal antibodies; from their debut to blockbuster status
They’re found in home-testing kits for pregnancy, hospital tests for MRSA, and in six out of ten of the best-selling drugs today. But monoclonal antibodies have kept a surprisingly low profile since their debut in a Nature paper in 1975. This podcast follows them from that time through patent wars, promising drug trials and finally to blockbuster status today. Includes contributions from LMB’s Greg Winter.
FORMA therapeutics and Cancer Research Technology to discover cancer drugs targeting deubiquitinating enzymes (DUBs)
LMB’s David Komander is part of collaborative consortium including FORMA Therapeutics and Cancer Research Technology, aiming to discover cancer drugs targeting deubiquitinating enzymes (DUBs). More…